Physician profile
Scott J Johnson
NPI 1609833219
$1,992.63
in general payments reported to CMS, 2019-2025
30 companies · $839 in 2025
The $839 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $313 · 2023: $145 · 2024: $450 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.65 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $288.30 | 2022-2025 | Axonics, Ams 700 |
| Urogen Pharma, INC. | $207.88 | 2021-2025 | Jelmyto |
| Teleflex LLC | $159.04 | 2021-2022 | |
| Procept Biorobotics Corporation | $156.61 | 2024-2025 | Aquabeam System |
| Ferring Pharmaceuticals INC. | $149.01 | 2024-2025 | Adstiladrin |
| Atricure, INC. | $136.72 | 2024 | |
| Abbvie INC. | $123.86 | 2021-2024 | |
| Astellas Pharma US INC | $102.18 | 2021-2023 | Myrbetriq |
| Tolmar, INC. | $86.27 | 2024-2025 | Eligard |
| Endo Pharmaceuticals INC. | $65.67 | 2022-2024 | Xiaflex |
| Axogen | $61.03 | 2025 | Axoguard Ha+ Nerve Protector |
| Coloplast Corp | $50.57 | 2021-2022 | |
| Endo USA, INC. | $45.76 | 2024 | Xiaflex |
| Progenics Pharmaceuticals, INC. | $41.65 | 2021-2023 | Pylarify |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $28.71 | 2022 | |
| Janssen Biotech, INC. | $25.93 | 2024 | Erleada |
| Sumitomo Pharma America, INC. | $23.60 | 2024 | Orgovyx |
| Blue Earth Diagnostics | $21.34 | 2024 | |
| Rochester Medical Corporation | $21.17 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.21 | 2025 | Azmiro |
| Verity Pharmaceuticals INC. | $19.98 | 2025 | Trelstar |
| Next Science LLC | $17.07 | 2024 | Blastx, Surgx, Xperience |
| Myriad Genetic Laboratories, INC. | $16.45 | 2021 | |
| Clarus Therapeutics INC. | $16.28 | 2021 | |
| Halozyme INC | $15.49 | 2023 | |
| Photocure INC | $14.95 | 2023 | Cysview |
| Antares Pharma, INC. | $14.92 | 2025 | Xyosted |
| Laborie Medical Technologies Corp. | $14.36 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.